Research map: Comparison of pharmacogenomic guidance in Australian prescribing resources and international pharmacogenomic guidelines
Back to the article
Papers in this map
- The Measurement of Observer Agreement for Categorical Data · John Richard Landis · 1977 · 81449 citations · Cited by this paper
- Methodological considerations in the pre‐implementation evaluation of AI ‐guided surgical antimicrobial prophylaxis · Areeha Mariam · 2026 · 1 citation · Related
- Interrater reliability: the kappa statistic · Marry L. McHugh · 2012 · 20219 citations · Cited by this paper
- Regulatory standardisation to improve the safety of continuous glucose monitoring systems in Australia and New Zealand: joint ADS / ADEA / ADIPS / ANZSPED / NZSSD statement · 2026 · Related
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update · JA Johnson · 2017 · 725 citations · Cited by this paper
- Race‐neutral lung function equations and clinical interpretation in East Asian patients · 2026 · Related
- Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group · PCD Bank · 2017 · 242 citations · Cited by this paper
- Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025 · 2026 · Related
- Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines · H. Abdullah-Koolmees · 2021 · 233 citations · Cited by this paper
- Assessing lung health disparities in Aboriginal Australians: inter‐community variation in spirometry pattern among adult Aboriginal people in rural and remote Australia · 2026 · Related
- The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021 · Renly Lim · 2022 · 136 citations · Cited by this paper
- Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service · 2026 · Related
- A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care · Santenna Chenchula · 2024 · 66 citations · Cited by this paper
- Trustworthy artificial intelligence for rural health care · 2026 · Related
- Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels · Deok Yong Yoon · 2020 · 36 citations · Cited by this paper
- Unravelling the paradox of smoking cessation in multimorbidity: the roles of polypharmacy and treatment burden · 2026 · Related
- Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources · Tyler A. Shugg · 2020 · 35 citations · Cited by this paper
- Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals · Angela N. Pearce · 2022 · 35 citations · Cited by this paper
- Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database · Emma Forton Magavern · 2025 · 22 citations · Cited by this paper
- CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx) · Cinzia Dello Russo · 2025 · 18 citations · Cited by this paper
- Does Cardiology Hold Pharmacogenetics to an Inconsistent Standard? A Comparison of Evidence Among Recommendations · Jasmine A. Luzum · 2018 · 15 citations · Cited by this paper
- The pharmacogenomic landscape of an Indigenous Australian population · Sumudu Rangika Samarasinghe · 2023 · 14 citations · Cited by this paper
- Key standards and principles for developing evidence-based clinical guidelines: balancing health professional, patient, funder, and government needs · Chau Thien Tay · 2025 · 14 citations · Cited by this paper
- Improving prioritization processes for clinical practice guidelines: new methods and an evaluation from the National Heart Foundation of Australia · Brooke Atkins · 2023 · 11 citations · Cited by this paper
- Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States · Mi-Jin Lee · 2023 · 11 citations · Cited by this paper
- Using pharmacogenomics to personalise drug therapy: which drugs, when and how · SOPHIE LENA STOCKER · 2025 · 10 citations · Cited by this paper
- Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study · Emma Ewasiuk · 2024 · 7 citations · Cited by this paper
- A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information · Loren Saulsberry · 2025 · 6 citations · Cited by this paper
- Utilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data‐linkage study · Chin Hang Yiu · 2024 · 5 citations · Cited by this paper
Source: OpenAlex (CC0)